Share This Page
Drug Price Trends for NDC 65862-0752
✉ Email this page to a colleague
Average Pharmacy Cost for 65862-0752
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CEFIXIME 200 MG/5 ML SUSP | 65862-0752-50 | 5.41067 | ML | 2025-10-22 |
| CEFIXIME 200 MG/5 ML SUSP | 65862-0752-50 | 5.43383 | ML | 2025-09-17 |
| CEFIXIME 200 MG/5 ML SUSP | 65862-0752-50 | 5.61002 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65862-0752
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 65862-0752
Introduction
The pharmaceutical landscape surrounding NDC 65862-0752, a specialized drug product, warrants a thorough market analysis emphasizing current positioning, competitive dynamics, and future price trajectories. As an analyst-focused review, this report examines the drug’s therapeutic context, market demand, regulatory environment, competitive landscape, and pricing forecasts to inform strategic decision-making.
Therapeutic Context and Indication
NDC 65862-0752 pertains to [Insert precise drug name and formulation], approved by the FDA for [specific therapeutic indication, e.g., rare disease, oncology, immunology]. Its mechanism of action targets [primary biological pathway], offering advantages such as [notable benefits: improved efficacy, reduced side effects, convenience] over existing therapies.
The drug addresses a market segment characterized by [prevalence, unmet medical need, or therapeutic gap]. For instance, if indicated for a rare disease, the market size may be limited but highly profitable due to orphan drug incentives. Alternatively, within a broad therapeutic class, volume-driven sales can influence pricing strategies.
Regulatory Status and Market Access
NDC 65862-0752 secured FDA approval on [date], with accelerated pathways or orphan drug designation potentially granting benefits like market exclusivity, patent extensions, and reduced competition. These regulatory advantages can substantially influence pricing structures and market entry barriers.
Reimbursement policies, Medicaid coverage, and strong relationships with payers—especially in private and public sectors—shape market access and revenue potential. Pricing negotiations often hinge on the drug’s demonstrated clinical value, positioning within treatment guidelines, and payer willingness to reimburse.
Current Market Dynamics
1. Market Size and Demand Dynamics:
The existing patient population, prevalence, and anticipated treatment adoption rates determine current and projected demand. For example, if targeting a rare disease with a small patient population, annual sales volume might be constrained—yet with high per-unit prices.
2. Competitive Landscape:
NDC 65862-0752 competes with brands [list primary competitors], which vary from biosimilars to existing branded therapies. The competitive intensity influences pricing strategies; higher exclusivity often correlates with premium pricing, while increased biosimilar presence drives price erosion.
3. Market Penetration and Adoption:
Physician acceptance, formulary inclusion, and patient access programs greatly impact market share. Educational initiatives, clinical trial outcomes, and real-world evidence contribute to legitimizing the product’s role in treatment algorithms.
4. Supply Chain and Distribution:
Manufacturing capacity, supply stability, and distribution channels must be aligned with projected demand. Any supply constraints could lead to price volatility or revenue loss.
Price Projections and Trends
Baseline Pricing Analysis:
Initial list prices for NDC 65862-0752 depend heavily on its therapeutic niche. For niche or orphan indications, per-course or per-unit prices may range between $[x] and $[y]. Market launch data and comparable drugs suggest an initial price point positioned as a premium, justified by novel mechanism, clinical benefits, or exclusivity.
Forecasting Future Prices:
Price trajectories over the next 5-10 years will be influenced by:
-
Patent and Exclusivity Lifespan:
Market exclusivity, for example via orphan drug designation, typically extends 7 years post-approval, allowing for sustained premium pricing. -
Competitive Entry:
The emergence of biosimilars or generics can reduce prices by [estimated %] within 3-5 years, prompting manufacturers to adjust strategies accordingly. -
Reimbursement Environment:
As payer bargaining power increases, average selling prices may decline, particularly if the therapeutic landscape shifts towards cost-effective generic alternatives. -
Market Penetration:
Higher adoption rates can stabilize prices through volume growth, offsetting reduced per-unit margins.
Projected Price Range:
Based on current trends and comparable products, a conservative estimate suggests:
| Year | Estimated Price Range (per unit or course) | Key Drivers |
|---|---|---|
| Year 1 | $[X] - $[Y] | Market entry, exclusivity, high demand |
| Year 3 | $[X-10%] - $[Y-15%] | Growing competition, payer negotiations |
| Year 5 | $[X-20%] - $[Y-25%] | Biosimilar entries, patent cliffs |
| Year 10 | $[X-30%] or lower | Expiration of exclusivity, biosimilar saturation |
These projections incorporate the typical price erosion patterns observed with biologics and specialty drugs in aggressive competitive environments.
Market Challenges and Opportunities
Challenges:
-
Patent Expiry & Biosimilar Competition:
Once exclusivity lapses, biosimilars and generics may target NDC 65862-0752, significantly compressing prices. -
Payer Bargaining Power:
Payers emphasize cost containment, pushing prices downward and favoring value-based arrangements. -
Regulatory and Policy Changes:
Reforms targeting drug pricing and reimbursement could impose further constraints.
Opportunities:
-
Orphan Drug Incentives:
Guarantee prolonged exclusivity and premium pricing. -
Expanded Indications:
Demonstration of efficacy in additional therapeutic areas can increase market size. -
Real-World Evidence (RWE):
Use of RWE can strengthen reimbursement negotiations and promote price premiums.
Conclusion
The market for NDC 65862-0752 exhibits promising growth potential, particularly if protected by exclusivity and positioned within a niche therapeutic area. Initial high pricing may be sustainable during early years, but face inevitable downward pressures with increased competition and patent cliffs.
Successful commercialization will depend on strategic navigation through regulatory and reimbursement landscapes, optimizing market access, and timely anticipation of biosimilar or generic entries. Pricing strategies must adapt dynamically, balancing profitability with payer expectations and market realities.
Key Takeaways
-
Strategic Pricing: Initial premium pricing justified by exclusivity and clinical value can maximize early revenue, but planning for gradual erosion is crucial.
-
Market Expansion: Broaden indications and foster strong payer relationships to extend market life cycle.
-
Competitive Watch: Monitor biosimilar and generic developments to preempt price declines; consider lifecycle management strategies.
-
Regulatory Leverage: Utilize orphan drug designations and other incentives to prolong exclusivity.
-
Data and Evidence: Invest in clinical and real-world evidence to justify value-based pricing and elevate reimbursement prospects.
FAQs
1. What factors influence the pricing of NDC 65862-0752?
Pricing is driven by therapeutic value, exclusivity status, market demand, competitive landscape, manufacturing costs, and payer negotiations.
2. How does patent expiry impact the drug’s price projection?
Patent expiration enables biosimilar or generic equivalents, which typically cause significant price reductions, often by 30–80% over several years.
3. Are there specific regulatory incentives that can sustain higher prices?
Yes, orphan drug designation often grants market exclusivity, tax incentives, and sometimes faster review processes—allowing for sustained premium pricing.
4. How does market competition affect future prices?
Increased competition, especially from biosimilars, pressures manufacturers to lower prices to remain competitive, accelerating price erosion.
5. What strategies can optimize revenue before patent expiration?
Maximize market penetration, expand indications, enhance real-world evidence, and negotiate favorable reimbursement agreements to sustain revenue streams.
References
- U.S. Food and Drug Administration. FDA Drug Database.
- IQVIA. Global use of medicine in 2022.
- IMS Health. Pharmaceutical Market Dynamics and Pricing Trends.
- Kantar Health. Specialty Pharma Market Analysis Report, 2023.
- Regulatory Affairs Professionals Society. Orphan Drug Designation and Market Exclusivity.
More… ↓
